Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in Europe for the treatment of iron deficiency, with or without anaemia. In this video, healthcare analyst Dr Sean Conroy provides an overview of Shield Therapeutics and outlines the company's strategy for the commercialisation of Feraccru. He finishes the video by detailing Edison’s approach to valuing the company.
See latest research note here.
09 Jul 2019
Shield Therapeutics - Executive interview
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Executive interview
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-3.7%) | Mkt Cap: 11.5m
- Published:
09 Jul 2019 -
Author:
Sean Conroy - Pages:
Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in Europe for the treatment of iron deficiency, with or without anaemia. In this video, healthcare analyst Dr Sean Conroy provides an overview of Shield Therapeutics and outlines the company's strategy for the commercialisation of Feraccru. He finishes the video by detailing Edison’s approach to valuing the company.
See latest research note here.